Lansen Pharmaceutical Holdings Limited provided consolidated earnings guidance for the six months ended 30 June 2019. For the six months, the company announced that the group expects to record a noticeable decrease in its net profit for the six months ended 30 June 2019 as compared with the net profit for the six months ended 30 June 2018. The decrease is mainly attributable to the following factors: as mentioned in the 2018 annual report, as a result of changes in pharmaceutical policies in China and adjustment in the Group's business strategies, the Group reduced its agency products. Among them, Yuze's agency arrangement has been terminated while that product still contribute a certain extend of revenue of the Group in the first half of last year; during the current period, it has made certain provisions and write-offs against its inventory; and the Group made an announcement on 21 June 2019 in relation to the non-exercise of the put option granted by Natural Dailyhealth Holdings Limited. Accordingly, the Group recorded a loss resulted from a write-off of the put option. The management of the Company sees improvement in operation from the new strategic initiatives.